Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Monness, Crespi, Hardt analyst Brian White downgrades Salesforce (NYSE:CRM) from Buy to Neutral.

byBenzinga Newsdesk

November 17, 2022

1 minute read

Monness, Crespi, Hardt analyst Brian White downgrades Salesforce (NYSE:CRM) from Buy to Neutral.

Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate

By Vandana Singh

Today, 2:41 AM

The FDA has granted Orphan Drug designation to Kiora Pharmaceuticals Inc’s (NASDAQ:KPRX) KIO-301 for Retinitis Pigmentosa. Retinitis Pigmentosa is an inherited genetic…

KPRX

News
Tech

Tesla Granted U.S. Design Patent D931,637 ‘Back seats’

By Charles Gross

Today, 2:41 AM

View patent here

TSLA

Industrias Bachoco Q3 Earnings Top Estimates

By Shivani Kumaresan

Today, 2:41 AM

Industrias Bachoco SAB De CV (NYSE:IBA) reported third-quarter FY21 sales growth of 10.6% year-on-year, to 20.2 billion Mexican pesos ($980 million),…

IBA

What Does HTG Molecular Diagnostics’ Debt Look Like?

By Benzinga Insights

Today, 2:41 AM

Shares of HTG Molecular Diagnostics Inc. (NASDAQ:HTGM) moved lower by 33.14% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

HTGM

Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Related Posts

Kiora Pharma Snags Orphan Drug Tag For Inherited Genetic Eye Disease Candidate

Tesla Granted U.S. Design Patent D931,637 ‘Back seats’

Industrias Bachoco Q3 Earnings Top Estimates

What Does HTG Molecular Diagnostics’ Debt Look Like?